Guggenheim lowered the firm’s price target on Nautilus Biotechnology (NAUT) to $2.50 from $4 and keeps a Buy rating on the shares. A key area of focus was on the commercial launch timeline, which was pushed out a year to the end of 2026 from a prior view of the end of 2025, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAUT: